{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:01:31Z","timestamp":1784548891401,"version":"3.55.0"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Hosp Pharm"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    Vancomycin is recommended as first-line treatment of methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MRSA) bacteremia, dosed by area-under-the-curve (AUC) with an assumed minimum inhibitory concentration (MIC) of 1\u2009mcg\/mL via broth microdilution. The purpose of this study was to compare effectiveness of AUC-based and trough-based dosing in MRSA bacteremia with an MIC\u2009&gt;\u20091 mcg\/mL via Etest.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This was a retrospective, observational cohort that compared vancomycin dosed by AUC or trough between January 1, 2017 and September 1, 2022. The primary outcome was a composite of treatment failure defined as peristent bacteremia\u2009\u2265\u20097\u2009days, inpatient mortality within 90\u2009days, or microbiologic relapse or readmission within 30\u2009days. Secondary outcomes compared nephrotoxicity, hospital and ICU length of stay, MIC differences, and difference in exposure measured by AUC.\n                    <jats:bold>Results:<\/jats:bold>\n                    Twenty-four patients in each group met inclusion criteria. For the primary outcome, there was no statistical difference in treatment failure between trough and AUC groups, respectively [10 (41.7%) vs 10 (41.7%),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20091.000]. There was no statistical difference in secondary outcomes, with incidence of nephrotoxicity [3 (12.5%) trough vs 2 (8.33%) AUC,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20091.000] and median AUC exposure over treatment course [502.9\u2009mcg.h\/mL (454.1-599.9) vs 474\u2009mcg.h\/mL (435.3-533),\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.312] similar between groups.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    There was no statistically significant difference in treatment failure for vancomycin by AUC or trough with an Etest MIC\u2009&gt;\u20091 mcg\/mL. Overall exposure to vancomycin and incidence of nephrotoxicty were numerically higher in the trough group, suggesting that dosing by AUC may limit exposure without impact on treatment failure.\n                  <\/jats:p>","DOI":"10.1177\/00185787231218922","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T02:33:29Z","timestamp":1703212409000},"page":"329-333","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Methicillin-Resistant\n                    <i>Staphylococcus aureus<\/i>\n                    Bacteremia Treated With Vancomycin Calculated by Area-Under-the-Curve in Patients With Elevated Vancomycin Minimum Inhibitory Concentrations"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0800-616X","authenticated-orcid":false,"given":"Sarah","family":"Arnold","sequence":"first","affiliation":[{"name":"MUSC Health Columbia Medical Center Downtown, Columbia, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Orvin","sequence":"additional","affiliation":[{"name":"St. Joseph\u2019s\/Candler Health System, Savannah, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malay","family":"Patel","sequence":"additional","affiliation":[{"name":"Atrium Health Navicent, Macon, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Schoen","sequence":"additional","affiliation":[{"name":"VA North Florida South Georgia Veterans Health System, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Wagner","sequence":"additional","affiliation":[{"name":"University of Mississippi School of Pharmacy, Jackson, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-2365","authenticated-orcid":false,"given":"Bruce M.","family":"Jones","sequence":"additional","affiliation":[{"name":"St. Joseph\u2019s\/Candler Health System, Savannah, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1801-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxaa036"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/8755122519852679"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.08.005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.6364"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/8755122515610125"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.521"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02215-10"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00448-13"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.02.002"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt340"},{"key":"e_1_3_2_15_2","volume-title":"Poster presentation presented at ASHP Midyear Meeting","author":"Patel M","unstructured":"Patel M, Schoen K, Arnold S, et al. Discrepancy in vancomycin minimal inhibitory concentration per Vitek2 and Etest in methicillin-resistant Staphylococcus aureus bloodstream infections. Poster presentation presented at ASHP Midyear Meeting. Las Vegas, NV; 2022 Dec. Available upon request."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz535"}],"container-title":["Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787231218922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00185787231218922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00185787231218922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:03:00Z","timestamp":1784545380000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00185787231218922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1177\/00185787231218922"],"URL":"https:\/\/doi.org\/10.1177\/00185787231218922","relation":{},"ISSN":["0018-5787","1945-1253"],"issn-type":[{"value":"0018-5787","type":"print"},{"value":"1945-1253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}